Introduction: Phospho-calcium balance disorders are very common in chronic hemodialysis. They are accompanied by a high risk of mortality, mainly due to cardiovascular complications. In this context, the KDIGO finalized recommendations updated to improve the quality of life of chronic hemodialysis and warn the complications which can engage the prognosis for survival. The objective of our study was to analyze the phosphocalcic status in Morocco chronic hemodialysis patients and to estimate the conformity of the results with the recommendations KDIGO. Materials and methods: This is a retrospective study over a period of 8 months from January to August 2018 which includes chronic hemodialysis patients followed at the laboratory of Biochemistry-Toxicology of the Moulay Ismail military hospital and the nephrology-hemodialysis clinic from Meknes. The biochemical parameters evaluated were determined on Cobas®6000 from Roche Diagnostics and then compared to the targets of the KDIGO recommendations. Results: A total of 86 patients were enrolled in the study. The average age of our patients was 44.86 ±12.65 years, with a sex ratio of 1.38. The percentages of patients with phosphocalcic data consistent with the KDIGO recommended targets for calcemia, phosphoremia and PTH1-84 were 75.5%, 50% and 43% respectively. Finally, 17.4% of patients met the KDIGO 2009 recommendations by combining all three criteria. Conclusion: The results obtained during this study should encourage clinicians to improve management of chronic hemodialysis patients.

Cancer is re-unowned by production of neoplastic cells. In cancer, un-developed cells are produced by bone marrow. After their entry into the blood normal cells are un-able to produce and cause anemia. Several oncogenes, including the p53, c-fms and Ras genes, can be activated by point mutations that change the amino acid sequence in the critical portion of protein. L-asparaginase is an enzyme which, by hydrolysis, produces aspartic acid and ammonia. It is used as medicine and in the food industry. It acts as a chemo-therapeutic agent to diagnose the ALL and lymphoproliferative syndrome. The level of Asparagine reduced in plasma decreases the formation of Deoxy ribonucleic acid and Ribonucleic acid. In ALL, asparaginase used in chemotherapy medicines for dealing the patients. it donates the important development in therapy results and helps achieve reform sullener approximately 90% of patients.